Brightgene bio-medical technology co.,ltd. (688166.SH): Dydrogesterone tablets and its active pharmaceutical ingredient, as well as the active pharmaceutical ingredient of dexmedetomidine tartrate, have been approved for marketing.

Zhitong Finance · Dec 3 16:16

Brightgene Bio-medical Technology Co.,Ltd. (688166.SH) announced recently that its wholly-owned subsidiary Brightgene Pharmaceutical (Suzhou) Co., Ltd...

According to the Zhitong Finance APP, Brightgene Bio-medical Technology Co.,Ltd. (688166.SH) recently announced that its wholly-owned subsidiary Brightgene Pharmaceutical (Suzhou) Co., Ltd. received the "Dienogest Tablets" Drug Registration Certificate, "Dienogest" and "Levonordefrin Hydrochloride" Chemical Raw Materials for Pharmaceutical Market Approval Notification. Dienogest is used to treat endometriosis. Levonordefrin Hydrochloride is for use in adult patients with severe acute hypotension.

The approval for the listing of Dienogest Tablets and its active pharmaceutical ingredient, as well as Levonordefrin Hydrochloride raw materials, further enriches the company's product pipeline.

The translation is provided by third-party software.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.

博瑞医药(688166.SH)：地诺孕素片及其原料药、重酒石酸去甲肾上腺素原料药获批上市

Brightgene bio-medical technology co.,ltd. (688166.SH): Dydrogesterone tablets and its active pharmaceutical ingredient, as well as the active pharmaceutical ingredient of dexmedetomidine tartrate, have been approved for marketing.

Risk Disclaimer

Statement